Form 4: Skorpios Trust Sells $27 Million Stake in Stoke Therapeutics

Skorpios Trust, along with related entities, disposed of 1,937,500 shares of Stoke Therapeutics at $14.05 per share, reducing their holdings but maintaining significant ownership.

Summary

• Skorpios Trust, along with Blue Horizon Enterprise Ltd. and Ezbon International Limited, filed a Form 4 detailing changes in beneficial ownership of Stoke Therapeutics, Inc. common stock.
• On September 19, 2024, Skorpios Trust sold 1,937,500 shares at a price of $14.05 per share.
• Following the transaction, Skorpios Trust indirectly owns 8,906,181 shares through its ownership of Blue Horizon Enterprise Ltd. and Ezbon International Limited.
• Blue Horizon Enterprise Ltd. directly owns 4,967,621 shares, and Ezbon International Limited directly owns 3,938,560 shares.
• Montrago Trustees Limited is the corporate trustee of Skorpios Trust.
• Each entity disclaims beneficial ownership of shares held by the others, except to the extent of their pecuniary interest.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. A large shareholder selling a significant stake can be perceived negatively by the market, but the remaining ownership is still substantial.

Negatives

• Skorpios Trust reduced its stake in Stoke Therapeutics by selling a significant number of shares.

Risks

• The sale of a large block of shares by a major shareholder could potentially exert downward pressure on the stock price.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or major shareholders of a publicly traded company buy or sell the company's stock. These filings provide transparency into the transactions of those with privileged information.

Stakeholder Impact

• Shareholders may react to the news of a large shareholder selling a portion of their stake.
• The sale could potentially impact the stock price in the short term.

Key Dates